慢性前列腺炎的UPOINT诊疗系统概述(5)
| 第1页 |
参见附件。
[39]Magri V， Wagenlehner F， Perletti G， et al. Use of the UPOINT chronic prostatitis/chronic pelvic pain syndrome classification in European patient cohorts： sexual function domain improves correlations.J Urol， 2010，184(6)：2339-2345.
[40]Hedelin HH.Evaluation of a modification of the UPOINT clinical phenotype system for the chronic pelvic pain syndrome.Scand J Urol Nephrol，2009，43(5)：373-376.
[41]Shoskes DA，Nickel JC，Kattan MW.Phenotypically directed multimodal therapy for chronic prostatitis/chronic pelvic pain syndrome： a prospective study using UPOINT.Urology， 2010 ，75(6)：1249-1253.
[42]Lee SW，Liong ML，Yuen KH，et al.Adverseimpact of sexual dysfunction in chronic prostatitis/chronic pelvic pain syndrome. Urology，2008 ，71(1)：79-84.
[43]Trinchieri A，Magri V，Cariani L，et al.Prevalence of sexual dysfunction in men with chronic prostatitis/chronic pelvic painsyndrome.ArchItal Urol Androl，2007，79(2)：67-70.
[44]Samplaski MK， Li J， Shoskes DA.Inclusion of erectile domain to UPOINT phenotype does not improve correlation with symptom severity in men with chronic prostatitis/chronic pelvic pain syndrome.Urology， 2011，78(3)：653-658.
[45]Brandon A Mahal，Jeffrey M Cohen，Stephen A Allsop，et al.The role of phenotypingin chronic prostatitis/chronic pelvic pain syndrome.Curr Urol Rep，2011，12(4)：297-303.
(收稿日期：2013-10-14)
您现在查看是摘要介绍页，详见PDF附件。